Ensign Group delivered record financial results for Q4 and FY 2025, fueled by exceptional clinical quality metrics and robust occupancy growth. For the full year, revenue increased 18.7% to $5.1 billion, while adjusted diluted EPS rose 19.5% to $6.57. Same-store occupancy reached an all-time high of 83.8%, supported by a 24% outperformance in state survey results and significant gains in Medicare (15.7%) and managed care (8.9%) revenue. Management issued strong FY 2026 guidance for EPS of $7.41 to $7.61 (14.3% growth at the midpoint) and revenue of $5.77 billion to $5.84 billion, driven by organic momentum and a disciplined M&A strategy backed by over $1 billion in liquidity.
| Metric | Value | Change |
|---|---|---|
| FY 2025 Revenue | $5.1 Billion | +18.7% |
| FY 2025 Adj. EPS | $6.57 | +19.5% |
| Q4 2025 Revenue | $1.4 Billion | +20.2% |
| Q4 2025 Adj. EPS | $1.82 | +22.1% |
| Same-Store Occupancy | 83.8% | All-time high |
| Net Debt/EBITDA | 1.77x | Record low |
| Cash & Equivalents | $504 Million | Strong liquidity |
Clinical quality is the primary driver of financial performance, creating a competitive moat through superior survey results and star ratings. Management reported that same-store operations outperformed peers by 24% at the state level and 33% at the county level in CMS surveys. This clinical excellence is directly translating into higher acuity patient volume, with Medicare days increasing 11% and skilled mix rising 8.5% in same-store facilities, proving that their 'patient-focused culture' is a viable revenue growth engine.
Ensign is actively evolving its M&A strategy to include higher-priced, newer assets, signaling a shift from purely distressed value-add to strategic platform expansion. The acquisition of the Stonehenge portfolio in Utah at a premium price highlights this pivot, justified by newer physical plants and immediate synergies. Despite rising valuations in a 'seller-friendly market,' the company maintains a robust pipeline of 82 operations acquired since 2024 and over $1 billion in 'dry powder' to continue deploying capital.
Operational efficiency and labor stabilization are providing margin tailwinds, with Director of Nursing (DON) turnover declining by 33% over the past few years. This leadership stability has led to lower agency usage and reduced overtime, even as occupancy hit record highs. The decentralized model, supported by a 'deep bench' of CEOs-in-training (AITs), allows the company to integrate acquisitions and improve labor metrics without corporate bottlenecks, supporting long-term margin expansion.
The company is leveraging its captive REIT, Standard Bearer, to diversify revenue and enhance real estate control. Standard Bearer added 12 assets during the quarter, bringing the total to 154 owned properties, and generated $34.5 million in rental revenue. This vertical integration allows Ensign to control its real estate destiny, as seen in the construction of a replacement facility for Grossmont Post Acute, ensuring capacity in key markets despite landlord changes or rising lease costs.
Rising acquisition prices pose a risk to future returns, with management explicitly noting the market has become 'seller-friendly' with 'values [that] have risen.' While they justify paying premiums for newer assets like the Stonehenge portfolio, these deals 'may take a bit longer to generate the returns we expect.' Investors should monitor if the pressure to deploy capital leads to a dilution of the high historical returns the company is known for.
Management highlighted 'variations in reimbursement systems, delays and changes in state budgets' as factors that could impact quarterly performance. Specifically, the introduction of new value-based purchasing (VBP) metrics and measures for healthcare-associated infections creates regulatory complexity. While management expressed confidence in their clinical data capabilities, any failure to adapt quickly to these specific quality metrics could result in reimbursement penalties.
The reliance on 'seasonality' as a variable for skilled mix and occupancy introduces near-term volatility. Management cautioned that 'skilled mix decline in the middle of the year' is typical, even if they hope for lighter seasonality. Additionally, the ramp-up of higher acuity patients can be complex; management noted that taking on facilities historically 'averse to acuity' can steepen the turnaround curve, potentially slowing the integration of new acquisitions.
Overall: Management exhibited a highly confident and enthusiastic demeanor throughout the call, frequently using superlatives like 'record,' 'amazing,' and 'extraordinary' to describe clinical and financial performance. There was a distinct emphasis on the 'humbling' nature of their operational success, attributing results to frontline caregivers rather than just corporate strategy. The tone shifted to pragmatic but optimistic during the Q&A regarding M&A pricing, acknowledging a 'seller-friendly' market while maintaining conviction in their disciplined underwriting.
Confidence: HIGH - Management provided specific, data-driven evidence to support their optimism, citing record occupancy, low leverage (1.77x), and a deep pipeline of deals. Their guidance for 14%+ growth in 2026 was delivered with certainty, bolstered by tangible metrics like declining turnover and increasing skilled mix.
$7.41 to $7.61 per diluted share
$5.77 billion to $5.84 billion
25%
~60 million
Hedging & Uncertainty: Management used minimal hedging regarding past performance, speaking definitively about 'record' results and 'all-time highs.' However, forward-looking statements regarding the M&A pipeline and seasonality included more qualifiers. Chad Keetch noted, 'I would probably describe the market as seller-friendly,' and Barry Port stated seasonality is 'somewhat of an unpredictable factor.' Despite these hedges, the overall language regarding guidance was firm, using phrases like 'we have confidence that we can achieve these results' rather than 'we hope to.' This suggests a high degree of visibility into their operations for the coming year.
We look forward to 2026 with confidence that our partners will continue to manage and innovate... - Barry Port, CEO
I would probably describe the market as seller-friendly in terms of values have risen. - Chad Keetch, CFO
We have complete faith in them and the culture that they've collectively built. - Barry Port, CEO
We're seeing tons of our traditional onesie-twosies... - Chad Keetch, CFO
We have evaluated multiple scenarios and based upon our strength in our performance... we have confidence that we can achieve these results. - Suzanne Snapper, CFO
Analyst Sentiment: Analysts were congratulatory and inquisitive, focusing heavily on the sustainability of M&A in a rising price environment and the mechanics of the labor turnaround. There was particular interest in the new VBP metrics and the company's ability to handle higher acuity patients.
Management Responses: Management responses were detailed and open, readily admitting to rising asset prices but justifying them with strategic logic. They demonstrated deep operational knowledge when discussing clinical protocols and labor metrics, reinforcing the narrative of a decentralized, clinically-driven organization.
M&A Pipeline and Valuations: Analysts asked about the diversity of sellers and rising valuations. Management confirmed a 'seller-friendly' market but emphasized their ability to underwrite premium assets.
Labor and Turnover: Discussion on the drivers of reduced agency labor and turnover. Management attributed success to leadership stability and local culture.
Medicare Reimbursement: Inquiries regarding new Value-Based Purchasing metrics. Management expressed confidence in their data capabilities and clinical quality to adapt.
Occupancy and Seasonality: Questions on the magnitude of occupancy growth baked into 2026 guidance. Management expects 2026 to mirror 2025's progress despite typical seasonality.
Ensign Group remains a premier growth story in the post-acute sector, successfully converting clinical excellence into financial outperformance. The company's decentralized model and culture have resulted in record occupancy (83.8%) and industry-leading quality metrics, which are driving double-digit revenue and EPS growth (19.5% in FY2025). The balance sheet is robust with $1 billion+ in liquidity and a low leverage ratio (1.77x), providing ample flexibility for M&A even as asset prices rise. The 14.3% growth guidance for 2026 appears conservative given the momentum in same-store occupancy and skilled mix. While rising acquisition costs and regulatory changes pose risks, Ensign's operational discipline and ability to integrate complex facilities justify a positive long-term outlook.
Management noted they are 'just now starting to see increased demand for our services related to the strong demographic trends,' suggesting a long-term tailwind for census.
The M&A market is described as 'seller-friendly' with 'pricing [that] has definitely gone up,' potentially compressing future returns on new investments.
Ensign is seeing improvements in turnover and wage growth stability, indicating that the extreme labor pressures of the past few years may be stabilizing.